Significant discrepancies exist when analyzing cancer treatment approaches in the United States and Europe. The US model, generally characterized by private insurance and a focus on innovation, often leads to early implementation of novel therapies, albeit at a significantly greater cost. In contrast, Continental systems frequently lean on public f